JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anne Samuel maintains an Overweight rating on Evolent Health and raises the price target from $36 to $45.
August 19, 2024 | 12:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Anne Samuel has increased the price target for Evolent Health from $36 to $45 while maintaining an Overweight rating. This suggests a positive outlook for the company's stock.
The increase in price target from $36 to $45 by a reputable analyst at JP Morgan indicates a strong positive sentiment towards Evolent Health's future performance. The Overweight rating suggests that the stock is expected to outperform the market, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100